



Review

Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease

D. Allan Butterfield ^{1,*} and Debra Boyd-Kimball ²

¹ Department of Chemistry and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506, USA

² Department of Chemistry and Biochemistry, University of Mount Union, Alliance, OH 44601, USA; boydkidl@mountunion.edu

* Correspondence: dabens@uky.edu

Received: 31 July 2020; Accepted: 29 August 2020; Published: 2 September 2020



Abstract: Oxidative and nitrosative stress are widely recognized as critical factors in the pathogenesis and progression of Alzheimer disease (AD) and its earlier stage, amnesic mild cognitive impairment (MCI). A major source of free radicals that lead to oxidative and nitrosative damage is mitochondria. This review paper discusses oxidative and nitrosative stress and markers thereof in the brain, along with redox proteomics, which are techniques that have been pioneered in the Butterfield laboratory. Selected biological alterations in—and oxidative and nitrosative modifications of—mitochondria in AD and MCI and systems of relevance thereof also are presented. The review article concludes with a section on the implications of mitochondrial oxidative and nitrosative stress in MCI and AD with respect to imaging studies in and targeted therapies toward these disorders. Taken together, this review provides support for the notion that brain mitochondrial alterations in AD and MCI are key components of oxidative and nitrosative stress observed in these two disorders, and as such, they provide potentially promising therapeutic targets to slow—and hopefully one day stop—the progression of AD, which is a devastating dementing disorder.

Keywords: oxidative and nitrosative stress; mitochondrial dysfunction; Alzheimer disease and mild cognitive impairment; redox proteomics; amyloid beta-peptide

1. Introduction

Alzheimer disease (AD) is the single largest cause of dementia in the aged population. In the United States, nearly six million persons have AD, with projections of between 15–20 million persons predicted to have AD within 30 years due to the aged-related nature of AD coupled to the very large Baby Boomer population in the USA (estimated to be up to 75 million Americans) [1]. The human and financial costs of this level of AD patients, in the opinion of the authors, make the future of AD a public health crisis for the USA and other countries that will require science-based interventions to slow the development or progression of AD [1].

The principal pathological hallmarks of brain in AD have been well described, i.e., extraneuronal deposits of fibrillar amyloid beta-peptide (A β) and dystrophic neurites (senile plaques, SP), intracellular accumulations of neurotoxic A β oligomers, intracellular deposits of hyperphosphorylated tau (neurofibrillary tangles, NFT), with tau being a key microtubule stabilizing protein, and synapse loss [2–4]. However, the complete molecular basis of AD remains elusive. Investigators have demonstrated that cognitive decline correlates well with A β oligomer and NFT loads, but not SP levels [2–4]. Consistent with the lack of correlation of SP with cognitive loss, therapeutic attempts to remove SP largely have not proven successful in modifying the course of AD [5]. An earlier stage of AD, amnesic mild cognitive impairment (MCI), is characterized by memory loss validated by an

independent observer with otherwise normal activities of daily living [6]. Pathology in MCI is similar to that in AD, albeit to a somewhat lesser extent [7].

Other factors may be involved in the progression of cognitive loss in AD. For example, oxidative and nitrosative stress in the brain are now widely recognized as key aspects of the pathogenesis and progression of AD and MCI [8–12]. Oxidative and nitrosative stress arise when the production of oxygen- or nitrogen-containing free radicals or reaction products of these two moieties exceed the cellular capacity to scavenge such species. As mentioned below, mitochondria are a major source of reactive oxidative stress and are involved in the production of nitrosative stress as well [8,13].

Consequently, this review will focus on mitochondria and oxidative and nitrosative stress in AD and MCI.

2. Mitochondria and Oxidative and Nitrosative Stress

Mitochondria are the principal source of ATP, which is formed by oxidative phosphorylation following electron flow through highly integrated protein complexes; however, mitochondria are also involved in many other functions as well, which, among others, include apoptosis, protein synthesis, and fatty acid oxidation [14,15].

Electrons supplied by reducing equivalents produced by glycolysis and the tricarboxylic acid cycle interact with Complex I of the electron transport chain (which in the case of NADH requires elaborate transport channels, since NADH cannot cross the inner membrane to the matrix). As electron flow occurs in the multiple redox-sensitive proteins within Complex I on the inner membrane, electron leak occurs, usually in the form of superoxide radical anion or the hydrogendioxide radical, elevating oxidative stress (Figure 1) [8,16,17]. Normally, superoxide free radicals are neutralized by mitochondrial matrix-resident manganese superoxide dismutase (MnSOD), producing hydrogen peroxide (H_2O_2) and molecular oxygen [16]. The former can be decomposed by catalase, but while this is an extraordinarily efficient enzyme it is often packaged in such a way as not to readily decompose this molecule. In that case, H_2O_2 , which has zero dipole moments and is therefore neutral and can diffuse into or through bilayers, can be decomposed to hydroxyl anion and the highly reactive hydroxyl free radical by Fe^{2+} or Cu^+ in a process known as Fenton chemistry [8,13].




Figure 1. In the process of oxidizing NADH by mitochondrial Complex I, oxygen is partially reduced to superoxide free radical, and a small percentage of leaks out. The protonation of superoxide radical anion leads to a non-charged free radical that can both easily penetrate and even cross the inner membrane lipid bilayer. Matrix-resident manganese superoxide dismutase (MnSOD) catalyzes the disproportionation of superoxide free radical into hydrogen peroxide and oxygen. H_2O_2 can react with any adventitious Fe^{2+} or Cu^+ to form the highly reactive hydroxyl free radical, which causes oxidative damage to any nearby protein or lipid. Moreover, H_2O_2 has a zero dipole moment, giving this molecule a non-polar character, which allows penetration into the lipid bilayer where lipid peroxidation may ensue. See the text for more details.

Other mitochondrial-related antioxidant systems include, among others, thioredoxin [18], peroxiredoxin 4 [19], glutathione peroxidase 4 [20], and methionine sulfoxide reductase A [21]. These enzymes play essential roles in maintaining redox homeostasis in mitochondria by exerting critical redox protective effects, including against protein oxidation. Consequently, dysfunctions in the activities of these enzymes are detrimental to cell survival.

Hydroxyl radical readily reacts with proteins and allylic H-atoms on the fatty acid tails of phospholipids and sphingolipids. The former leads to the incorporation of carbonyl functionalities in proteins and alterations in protein conformation (and normally loss of function as a consequence) [8,22–24], while OH-mediated allylic hydrogen atom abstraction from unsaturated lipid acyl chains initiates the processes of lipid peroxidation, leading to highly reactive nucleophilic unsaturated aldehydes such as 4-hydroxynonenal (HNE) (Figure 2A) [8,13,25–27]. Protein conformation is also altered with loss of function by HNE that binds to and changes the structure of proteins [28].

Nitrosative stress usually follows the production of nitric oxide (NO), which is formed by the decomposition of arginine catalyzed by the enzyme nitric oxide synthase (NOS) [29]. In the brain, neuronal NOS is involved in glutamatergic neurotransmission processes and requires Ca^{2+} . Inducible NOS (i-NOS) does not require Ca^{2+} and is key to nitrosative stress in the brain. When superoxide radical anion (for example from mitochondria) and NO (also a free radical) meet, their reaction rate is extremely high, and in the presence of CO_2 leads to the formation of nitrogen dioxide (NO_2) [29]. The formation of 3-nitrotyrosine (3-NT) on proteins occurs when the phenolic H-atom of tyrosine is removed by a radical attack followed by electron delocalization to the 3-position of Tyr and radical–radical recombination of this radical with NO_2 occurs (Figure 2B). With the NO_2 functionality on Tyr, tyrosine phosphorylation by tyrosine kinases, including receptor tyrosine kinases, is inhibited due to steric interference of the NO_2 group with the active site of the enzyme. This modification can provide detrimental consequences for cell survival [8,13,29,30].




Figure 2. (A) Mechanism of lipid peroxidation. Arachidonic acid structure showing labile allylic H-atoms that are subject to free radical-mediated abstraction (Rxn 1) leading to carbon-centered free radical on the lipid-resident arachidonic acid carbon backbone. Paramagnetic molecular oxygen, in a radical–radical recombination reaction (Rxn 2), produces the lipid-bound peroxy free radical. This latter free radical abstracts another labile allylic H-atom (Rxn 3) to form the lipid hydroperoxide and another carbon-centered free radical. Then, this latter radical takes part in Rxn 2 again, i.e., a chain reaction, that will continue as long as there are molecular oxygen and allylic H-atoms present. The lipid hydroperoxide is decomposed into reactive aldehydes, including the highly reactive 4-hydroxynonenal (HNE). See text for additional details. (B). Formation of 3-nitrotyrosine. Nitric oxide (NO), a free radical produced by nitric oxide synthase from arginine, reacts with superoxide free radical anion (see Figure 1) by radical–radical recombination to form peroxynitrite, ONOO[−]. The actual next reaction shown is more complicated than depicted, but in essence, the protonation of peroxynitrite forms peroxynitrous acid that decomposes into the free radical nitrogen dioxide (NO₂) and hydroxyl free radical. Tyrosine, attacked by a free radical R[·] to remove the H-atom of the phenolic OH group, leaves an unpaired electron on the O-atom that delocalizes to the 3-position of tyrosine with the H-atom removed from the 3-position, reforming the OH functional group on Tyr. NO₂ reacts with the delocalized unpaired electron on the 3-position of tyrosine residues in a radical–radical recombination reaction to form 3-nitrotyrosine (3-NT), which is a major marker of nitrosative stress. See the text for further details.

3. Selected Biological Alterations in AD Mitochondria

While mitochondria have a principal function of producing ATP, other functions also are important and relevant to AD. As one example, elegant research from Mahley's laboratory demonstrated in Neuro-2a neuronal cells expressing stable isoforms of apolipoprotein E (apoE), i.e., apoE2, apoE3, or apoE4, with the latter a major risk factor for developing AD, that apoE4 is excessively produced by damaged neurons [31]. Since the structure of apoE4 is different, due to the lack of Cys residues, compared to two key Cys residues in apoE2 and one key Cys residue in apoE3 [32], apoE4 is subject to proteolysis. The resulting apoE4 fragments were demonstrated by the Mahley laboratory to be neurotoxic, specifically negatively affecting tau biology and mitochondrial function [31]. For the latter, mitochondrial respiration (as well as glycolysis) was negatively affected under basal conditions, but if stressed or damaged, apoE4 neurons had half the ATP reserve capacity of apoE3 neurons. A lower NAD^+/NADH ratio and elevated ROS and mitochondrial Ca^{2+} also were observed. These changes were correlated to proteomics-identified altered levels of proteins associated with mitochondrial fission/fusion dynamics among other mitochondrial proteins [31]. The researchers suggested that important therapeutic targets for AD emerged from these studies.

The lack of Cys residues in apoE4 has been hypothesized to contribute to the increased risk of developing AD, since the lipid peroxidation product HNE would not be able to be scavenged (unlike the case for apoE2 and apoE3) and thereby bind to and modify the structure and function of mitochondrial proteins in AD and MCI [33]. It is conceivable that the studies of Mahely [31] and Butterfield [33] have significant overlap, although other studies would be required to test this notion.

Consonant with the above studies, Swerdlow [34] posited the existence of primary and secondary mitochondrial cascades as critical for AD. Primary mitochondrial cascades in AD are hypothesized to be due to diminished glucose metabolism in an AD brain and in tissues outside the brain. The latter is suggested to indicate that $\text{A}\beta$ peptide is not needed for mitochondrial dysfunction. The secondary mitochondrial cascade important in AD posited by Swerdlow involves $\text{A}\beta$ oligomer-induced changes in mitochondrial function, as well the presence of a dehydrogenase, amyloid-binding alcohol dehydrogenase (ABAD), in mitochondria, that leads to elevated free radicals, consequent altered glycolytic and mitochondrial proteins structure and function, and resultant Ca^{2+} elevation, causing neuronal death. As Swerdlow suggests, both mitochondrial cascades could be occurring simultaneously [34].

In a recent reviews and discussed further below, evidence was collected for altered glucose metabolism associated with $\text{A}\beta$ -mediated lipid peroxidation and protein oxidative damage to glycolytic and mitochondrial enzymes, ion-motive ATPases, the opening of voltage-gated Ca^{2+} channels with resulting Ca^{2+} elevation in endoplasmic reticulum and mitochondria, and consequent neuronal death [8,35]. This would suggest support for the Secondary Mitochondrial Cascade hypothesis for AD. Moreover, mitochondria isolated from lymphocytes from persons with AD and MCI showed elevated oxidative damage that correlated inversely with cognitive performance [36,37]. Redox proteomics identified similar proteins as identified in AD and MCI brains as oxidatively modified, and these included mitochondrial ATP synthase [36,37]. Consequently, evidence consistent with the tenants of the Primary Mitochondrial Cascade hypothesis were obtained, suggesting, similar to that posited by Swerdlow, both cascades are in play in AD and MCI that coalesce in the brain as decreased glucose metabolism evidenced by altered glycolysis and mitochondria. This concept is discussed further below.

Mitochondria are not static organelles. For example, anterograde and retrograde axonal transport of mitochondria by kinesin and dynein, respectively, along microtubule assemblies are needed to provide pre-synaptic membranes, vesicles, etc. with sufficient ATP to permit neurotransmission and regulate neuronal function and to return to the neuronal cell body to be recharged. Other dynamics in which mitochondria are involved are fission and fusion. Among other functions, mitochondrial fission is involved in the regulation of mitophagy, apoptosis, and the cellular need for ATP [38]. In contrast, mitochondrial fusion leads to large moieties that combine contents of multiple mitochondria, which also leads to pleiotropic functions, among which is a larger assembly of mitochondrial DNA that is

needed to produce a subset of mitochondrial proteins [38]. The role of dynamin-related protein-1 (Drp-1) in these processes has been extensively investigated [39]. Drp-1 is critically important for mitochondrial fission, but when its expression is lowered, there is some evidence that Drp-1 may play a role in mitochondria fusion as well [39]. Drp-1 is a GTPase, and the enzyme activity allows Drp-1 to dissociate from the receptor that was ligand-activated. This GTPase is highly susceptible to post-translational modification (PTM). Among the various PTMs, S-Nitrosylation of the GTPase activity region of Drp-1 leads to a loss of activity and in a mutant APP/PS1 transgenic mouse model of AD, it leads to neurotoxicity [39]. The inhibition of mitochondrial fission with mitochondrial division inhibitor-1 (Mdivi-1), which indirectly inhibited Drp-1, protected against the production of reactive oxygen species (ROS), loss of anterograde mitochondrial transport, damage to synapses, neuronal death, and stunted growth of neuritic spines, all of which were observed in untreated mice [40,41]. Decreased mitochondrial fragmentation was observed in vitro using N2a neuronal cells treated with Mdivi-1 prior to challenge with neurotoxic A β [42].

4. Redox Proteomics

Redox proteomics is a subset of proteomics methods used to identify oxidatively or nitrosatively modified proteins [43]. The authors of this section of the review focus on redox proteomics applied to studies of relevance to AD, MCI, and preclinical AD. Redox proteomics was pioneered in the Butterfield laboratory [44], and the reader is directed to comprehensive reviews of redox proteomics applied to neurodegenerative disorders and AD specifically [45–52], as well as a recent review of redox proteomics applied to studies of A β in in vitro and in vivo investigations and in studies of AD and MCI [35].

Redox proteomics adopts many of the methods of expression proteomics, i.e., separation of proteins of interest, i.e., those that are oxidatively or nitrosatively modified (indexed by protein oxidation employing protein-resident carbonyls and 3-NT, or lipid peroxidation, indexed by protein-bound HNE). These proteins are modified by appropriate tagging strategies to identify subject versus control proteins, which is followed by the digestion of proteins with trypsin and the separation of tryptic peptides often through ion-exchange columns followed by reverse-phase chromatography, with each tryptic peptide injected into a high-response mass spectrometer operating in MS/MS mode. This approach allows for the amino acid sequence of separated peptides to be determined, from which the identification of the proteins involved can be determined by interrogating various databases. The relative heights of mass peaks of each peptide from control and AD brain specimens, with different markers on the control and AD peptide being examined, give the investigator knowledge of the relative abundance of the proteins of interest. For much more detailed descriptions of the methods involved in redox proteomics, the reader is referred to a descriptive analytical review paper [46].

As will be further described below, the application of these methods to in vitro cellular models, in vivo animal models, and human brain from AD and MCI and respective control subjects, with emphases on mitochondrial proteins identified will be the subject of the remaining aspects of this review paper. An important point is that in all studies from our laboratory at the University of Kentucky, post-mortem intervals of brain from which specimens were obtained were typically in the range of 2–4 h. Any longer times, in our opinion, would render interpretations of redox proteomics results as less than reliable for obvious reasons.

5. Oxidative and Nitrosative Modifications of Mitochondrial Proteins in AD and MCI and in Systems of Relevance Thereof

As mentioned above, the use of redox proteomics has led to the identification of oxidized proteins, as indexed by carbonylation, nitration, and modification with HNE, in both in vitro and in vivo models of AD in addition to MCI and AD brain. Consistent with the hypothesis that both oxidative stress and mitochondrial dysfunction are early events in the progression of AD [12,35,53], many of the oxidized

proteins identified are mitochondrial proteins involved in metabolism, protein synthesis and folding, ROS scavenging, transport, and apoptosis (Table 1).

Table 1. Summary of oxidatively modified mitochondrial proteins identified by redox proteomics and enzymatic activity in mild cognitive impairment (MCI) and Alzheimer disease (AD).

Protein	Oxidative Modification	Disease State	Brain Region	Activity	Reference
Aconitase	H	Late AD	Hippocampus	↓	[54]
MDH	H	Early AD	IPL	↑	[55]
LDH	H	MCI	Hippocampus	↓	[56]
ATP Synthase	H	MCI	Hippocampus	↓	[56]
	H	MCI	IPL	↓	[56]
	H	Early AD	IPL		[55]
	H	Late AD	IPL	↓	[54]
	N	Late AD	Hippocampus		[57]
MnSOD	H	Early AD	IPL	↓	[55]
	H	Late AD	IPL		[54]
EF-Tu	H	MCI	IPL		[56]
HSP70	H	MCI	Hippocampus		[56]
	N	MCI	Hippocampus		[58]
	C	MCI	IPL		[59]
HSP90	C	MCI	IPL		[60]
VDAC1	N	Late AD	Hippocampus		[57]

C, carbonylation; N, nitration; H, HNE bound.

Several proteins associated with catabolism and mitochondrial ATP generation are oxidized in MCI and AD brains (Figure 3). These include the tricarboxylic acid cycle enzymes aconitase in late AD [54] and malate dehydrogenase (MDH) in early AD [55] and the alpha-subunit of ATP synthase, or complex V of the electron transport chain, in MCI [56], early AD [55,61], and late AD [54,57]. Aconitase is an iron–sulfur protein that catalyzes the interconversion of citrate and isocitrate [62] and is a redox-sensitive enzyme that is significantly modified by HNE in late AD hippocampus [54] and by carbonylation induced by A β in vivo [63]. MDH catalyzes the oxidation of malate to oxaloacetate with the reduction of NAD⁺ to NADH, but it also plays a critical role in the malate–aspartate shuttle that maintains the redox status of the cytosol by shuttling electrons from NADH in the cytosol to NAD⁺ in the mitochondrial matrix [64]. MDH is oxidatively modified by HNE in early AD inferior parietal lobule (IPL) [55] and its carbonylation is induced by A β in vitro and in vivo [63,65,66]. Lactate dehydrogenase-B (LDH) is also present in mitochondria [67] and is oxidatively modified by HNE in MCI hippocampus [56]. LDH is found preferentially in aerobic tissues [68] and allows neuronal mitochondria to utilize lactate imported by monocarboxylate transporter 2 (MCT2) as a fuel source by oxidation to pyruvate from which acetyl CoA can be produced and condensed into the tricarboxylic acid cycle at citrate synthase [67,69,70]. ATP synthase utilizes the protein gradient established across the inner mitochondrial membrane by the electron transport chain to drive the phosphorylation of ADP to yield ATP [71,72]. The carbonylation of ATP synthase is induced in vivo by A β [73], and it is significantly modified by HNE in MCI hippocampus and IPL [56], early AD IPL [55], and late AD IPL [54] in addition to being significantly nitrated in late AD hippocampus [57]. The activity of each of these oxidatively modified enzymes is affected in MCI and AD brains. The activities of

LDH, aconitase, and ATP synthase are significantly decreased as a result of oxidation [54–56,61] and consistent with the hypometabolism prevalent in MCI and AD brain [74–76]; however, the activity of MDH is significantly increased [55]. It is unclear why the oxidative modification results in structural change that increases the activity of MDH; however, the increased activity could be a compensatory mechanism in response to the oxidative damage of other key energy-related proteins including a number of glycolytic enzymes [35].




Figure 3. Redox proteomics identified oxidatively modified, mitochondrial proteins in brains from persons with Alzheimer disease or amnesic mild cognitive impairment. Proteins marked with a red star are oxidatively modified. Functional classes of oxidatively dysfunctional proteins include those related to: Glucose metabolism, i.e., lactate dehydrogenase (LDH), aconitase, malate dehydrogenase (MDH), ATP synthase; Export of anions (ATP, for example, has a decreased chance of export through voltage-dependent anion channel 1 (VDAC1) to drive neuronal function including the maintenance of mitochondrial potential); Free radical scavenging (MnSOD, which increases opportunities to cause further oxidative and nitrosative damage to mitochondria); mitochondrial protein synthesis (EF-Tu, which would lead to altered levels of key proteins needed to assemble into functional inner membrane resident electron transport complexes and thereby decrease ATP levels); and chaperone and transport function for the import of nuclear-encoded proteins into mitochondria (heat shock protein 70 (HSP70); heat shock protein 90 (HSP90), which also could contribute to altered protein levels of needed electron transport chain [ETC] complexes and other key proteins]. See text for further details.

Proteostasis is the maintenance of the proteome ensuring that all proteins are correctly folded, localized, and concentrated for their function. Mitostasis refers specifically to mitochondrial proteostasis [77]. Mitochondria possess both circular DNA and a transcription–translation machinery [78]. EF-Tu is a mitochondrial elongation factor responsible for coordinating the binding of amino acyl-tRNA to the codon [79] and is significantly modified by the lipid peroxidation product HNE in MCI IPL [56]. The oxidation of EF-Tu could lead to altered function and the incorrect translation of mitochondrial proteins, which include 13 components of the electron transport chain [78].

While mitochondria possess their own DNA and transcription and translation machinery, most mitochondrial proteins are encoded in nuclear DNA, and the protein product needs to be transported into mitochondria from the cytosol in an unfolded state [77]. Heat shock protein 70 (HSP70) and heat shock protein 90 (HSP90) are chaperones that interact with the outer mitochondrial membrane,

stabilizing the unfolded state of the nascent proteins and thereby preventing aggregation, and they are required for transport of the protein into mitochondria through the translocase Tom70 [80]. Both HSP70 and HSP90 are significantly carbonylated in MCI IPL [59,60], while HSP70 is modified by both HNE and 3-NT in an MCI hippocampus [56,58]. Oxidation of these chaperones may prevent the formation of appropriate interactions with protein targets, resulting in protein misfolding and aggregation, thereby impacting the transport of nuclear encoded proteins into mitochondria.

MnSOD, or superoxide dismutase 2 (SOD2), is a homotetramer localized to the mitochondrial matrix. MnSOD catalyzes the conversion of superoxide radical anion into H_2O_2 and O_2 [81–83], and its expression is increased in AD hippocampus [84]. MnSOD is oxidatively modified by HNE in early AD IPL, resulting in a significant decrease in enzyme activity [55] and is also oxidatively modified by HNE in late AD IPL [54]. Decreased activity of MnSOD would result in a decreased capacity to scavenge superoxide radical anion propagating free radical damage to mitochondrial components resulting in further mitochondrial dysfunction. MnSOD activity is suppressed by the binding of p53 [85]. p53 is a nuclear transcription factor that translocates to the mitochondria as a result of stress, including ROS, leading to apoptosis and necrosis. Translocation leads to an accumulation of p53 in the mitochondrial outer membrane and binds to inhibitors of apoptosis proteins, Bcl-2 or Bcl-xL, which releases Bax and Bak and thereby contributes to the formation of a mitochondrial permeability transition pore (MPTP) and release of cytochrome c. p53 can also accumulate in the inner mitochondrial membrane and mediate the opening of MPTP in the inner mitochondrial membrane [86]. p53 is significantly increased in MCI and AD IPL with p53 significantly modified by protein-bound HNE, 3-NT, and carbonyls in an AD brain. p53 is significantly modified by carbonylation, but not 3NT or HNE in MCI IPL [87,88]. Protein expression of MnSOD was significantly increased in mitochondria isolated from the brain of p53 knockout mice [89], which is consistent with the p53 transcriptional repression of MnSOD [90,91]. This relationship is suggested to fine-tune the cellular response to oxidative and nitrosative stress [92], but oxidative damage to MnSOD and p53 in MCI and AD brain may affect this interplay, which contributes to apoptosis [93] and to the spread of ROS and subsequent oxidative damage beyond the subcellular localization of the mitochondria.

The voltage-dependent anion channel 1 (VDAC1), located in the outer mitochondrial membrane, regulates mitochondrial membrane permeability [94] and is significantly nitrated in late AD hippocampus [57]. VDAC1 regulates the entry of metabolites (i.e., pyruvate, malate, and succinate) and ions in addition to the exit of hemes and ROS. Thus, VDAC1 mediates communication and traffic between mitochondria and the cytosol [95]. The N-terminal domain of VDAC1 interacts with several Bcl-2 family proteins that regulate apoptosis and is involved in gating the channel [96–101]. A dynamic equilibrium between monomeric and oligomeric states of the protein exist, with the oligomeric state being formed upon apoptotic induction resulting in a channel through which cytochrome c efflux can occur [94]. VDAC1 inhibitors prevent oligomerization and the induction of apoptosis even in the presence of pro-apoptotic stimuli [102], indicating that apoptotic induction can be driven by VDAC1 oligomerization. VDAC1 overexpression, which favors oligomerization and promotes apoptosis [103], is present in AD brain and increases as the disease progresses [104]. The hexokinase isoform HK-I binds to the N-terminus of VDAC1 on the cytoplasmic side of the outer mitochondrial membrane and has been shown in both in vitro and in vivo systems to protect against apoptosis [105,106]. $A\beta(1-42)$ also directly interacts with the N-terminus of VDAC1 and induces HK-I release, resulting in VDAC1 oligomerization, cytochrome c release, and apoptosis in SH-SY5Y cells [107]. The oxidative modification of VDAC1 by 3-NT in AD brain could induce apoptosis by affecting the structure of the protein to either promote HK-1 release or oligomerization directly. Further study is needed to distinguish between these possibilities.

Taken together, the oxidative modification of proteins critical for maintaining cellular energy and redox status, metabolite, and ion transport, the translation of mitochondrial encoded proteins, and the import of nuclear-encoded proteins could play a critical role in the mitochondrial dysfunction observed early in the pathogenesis and progression of AD.

Oxidative stress has also been characterized in mitochondria isolated from peripheral cells in MCI and AD. Levels of protein-bound carbonyls, 3-NT, and HNE are significantly increased in mitochondria isolated from lymphocytes of MCI and AD patients, which correlate with elevated A β levels, decreased levels of small molecule antioxidants, and decreased cognitive test performance [36,37]. Further study using quantitative proteomics identified protein expression alterations in mitochondria isolated from both MCI and AD lymphocytes. These proteins can be categorized as involved in energetics, structural integrity, cell signaling, and antioxidant defense [37]. Interestingly, significant increases in all the proteins affected in MCI lymphocyte mitochondria were detected. Notably, these proteins included LDH-B and the β -subunit of ATP synthase, indicating an upregulation to meet the energy needs of the cells early in the disease process that does not persist into the development of AD. Consistent with a possible compensatory mechanism in the progression of the disease is a significant increase in the activity of electron transport chain complexes II and IV reported in mitochondria isolated from AD lymphocytes [108]; however, in mitochondria isolated from AD platelets, the activity of complex IV, or cytochrome c oxidase, is significantly decreased [109–111], indicating differences in the stage of disease at which the samples were obtained or differences in cellular responses. The activity of aconitase is significantly decreased in mitochondria from both MCI and AD lymphocytes [112].

In addition to the redox proteomics results described above that identified proteins with elevated markers of oxidative and nitrosative modifications to proteins in AD brain or models thereof such as protein carbonyls, 3-NT, and protein-bound HNE, another important index of protein nitrosative modification is S-nitrosylation. Nitric oxide-mediated reactions with intermediate oxidation states of Cys thiol moiety lead to nitrosylation of the S-atom of this amino acid in proteins. Most often, such modifications inhibit protein functions. Selected studies of the S-nitrosylation proteome in AD identified key proteins with altered functions associated with antioxidant, glycolysis, mitochondrial export, calcium homeostasis, synapses, apoptosis, mitochondrial dynamics, protein folding, and neuroinflammation, among other functions [113–116]. Many of these proteins are the same as those modified by other indices of oxidative and nitrosative stress noted above. This observation is consistent with the notion that specific proteins are more vulnerable to oxidative and nitrosative damage in the AD brain than other proteins.

There has been a long-standing debate as to whether oxidative stress, including damage indexed by protein oxidation and lipid peroxidation, is involved in the mechanisms leading to AD or consequences of AD neuropathology and altered neurochemistry and neurophysiology [117]. In our opinion, this is not a case of “either or”, but rather, “both and”. A β 42 oligomers cause oxidative damage as mentioned above, and these oligomers also lead to synaptic dysfunction correlated with cognitive loss [8,9,26]. Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].

More research is needed to understand the impact of increased protein oxidation and lipid peroxidation on the mitochondrial proteome, and a focus on mitochondria from peripheral tissues may lead to the identification of potential biomarkers that are so desperately needed.

6. Implications of Mitochondrial Oxidative and Nitrosative Stress in MCI and AD: Correlations with Imaging Studies and Targeted Therapies

The human brain comprises approximately 2% of body mass but consumes approximately 20% of daily oxygen intake [118]. In the brain, ATP is required for neurotransmitter synthesis, protein turnover, neurotransmission, transport, and maintenance of ion gradients [119]. The high metabolic need of the brain cannot be met by glycolytic activity. Rather, neurons rely on the tricarboxylic acid cycle and oxidative phosphorylation housed in mitochondria to produce ATP [72,120]. However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74–76]. Oxidative modification and the decreased activity of several key glycolytic enzymes in MCI and AD brain are consistent with the observed glucose hypometabolism [35]. While glucose is a preferred fuel of the central nervous system, lactate and ketone bodies such as 3- β -hydroxybutyrate and acetoacetate can be utilized by neurons [121]. Unlike glucose metabolism, ketone metabolism

does not appear to be altered in the early progression of AD, as ketones are used at the same rate in MCI and early AD as in the control brain [122,123]. Further research is needed to determine if ketone supplementation is beneficial.

Astrocytes express glucose-6-phosphatase- β (G6Pase- β) and are thus capable of gluconeogenesis, or the synthesis of glucose from non-carbohydrate precursors such as aspartate, glutamate, alanine, and lactate [124]. This suggests that gluconeogenic activity in astrocytes could function to build up a glucose concentration gradient to boost the flow of glucose from astrocytes to neurons [125]. Under oxidative stress, glucose in the brain is not only needed to produce ATP, but it would be diverted to produce much needed NADPH via the pentose phosphate pathway to replenish thiol-containing antioxidants such as thioredoxin, peroxiredoxin, and glutathione, as the oxidative reactions that produce NADPH are irreversible and require glucose-6-phosphate as a substrate [126]. A recent study demonstrated apoE4 isoform-specific differences in astrocytic glucose utilization in vitro. Compared to the apoE2 or apoE3 isoforms, astrocytes expressing the apoE4 isoform exhibited increased lactate synthesis, pentose phosphate pathway flux, and gluconeogenesis [127]. Further study is necessary to determine if these isoform-specific differences in glucose utilization occur in vivo.

Neurons could also use glucogenic or even ketogenic amino acids to generate TCA intermediates to produce ATP through oxidative phosphorylation when glucose is scarce [128]. Glutamate and glutamine are the most abundant amino acids in the human brain [129]. Glutamate is produced from the transamination of α -ketoglutarate where branched-chain amino acids likely serve as the amine donor resulting in the formation of their respective α -keto acids, which could be further catabolized to yield propionyl-CoA, succinyl-CoA, and acetyl-CoA [130]. Glutamine is produced from glutamate by the activity of glutamine synthetase (GS) [124,131]. Glutamate functions as an excitatory neurotransmitter and a glutamate–glutamine cycle exists between astrocytes and neurons, allowing for the movement of anaplerotic carbon units and the sequestration of ammonia, which is neurotoxic [132]. However, the use of such amino acids as a compensatory energy supply is likely not a long-term solution. Amino acid levels can become quickly depleted, and the oxidative modification of necessary enzymes and transporters could diminish the ability of neurons to utilize these alternative energy sources. The glial glutamate transporter (GLT-1), also known as the excitatory amino acid transporter-2 (EAAT2), is responsible for the uptake of synaptic glutamate, but its activity is decreased in AD brain, which is likely due to oxidative modification by HNE [26,131]. GS is also oxidatively modified in both MCI and AD brain [44,54,59], likely resulting in the significantly decreased activity observed in AD brain [133,134]. Metabolomic studies of MCI and AD CSF and plasma report altered levels of amino acids compared to controls, indicating that alterations in amino acid metabolism are present in AD [135,136]. More research is necessary to understand the complex network of metabolic perturbations in AD.

Efforts continue to be placed on the early detection of AD as changes in brain chemistry begin to occur 20 years or more prior to the onset of noticeable cognitive symptoms [137–140]. A recent longitudinal study of asymptomatic autosomal dominant carriers of AD provided further insight into the progression of brain chemistry changes with A β deposition occurring first, followed by hypometabolism, and finally structural atrophy [141]. These observations are consistent with our hypothesis that A β -oligomer-induced oxidative stress impairs glucose metabolism, contributing to mitochondrial dysfunction, leading to synaptic dysfunction, and eventually resulting in neuronal death (Figure 4) [8,142]. While the deposition of A β occurs early in the progression of the disease [141], oligomeric A β rather than fibril A β is regarded as the toxic species of this peptide [143–146]. Oligomeric A β is a precursor to fibrillar A β and this hydrophobic peptide, unlike fibrils, is small enough to solubilize in lipid bilayers. Accordingly, membrane-resident oligomeric A β is present and induces oxidative damage (lipid peroxidation) prior to the detection of A β deposition [8], which is consistent with the observation that the disease is initiated decades before the onset of cognitive symptoms. The presence of A β oligomers in mitochondrial membranes is consistent with A β -induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53]. Consequently, there is growing evidence

that interventions to prevent or delay the onset of AD need to occur decades prior to the onset of cognitive symptoms.




Figure 4. Mitochondrial dysfunction related to oxidative and/or nitrosative stress that is in turn associated with amyloid β -peptide oligomer inserted in the mitochondrial membranes. Consequences of these oxidative or nitrosative stress-mediated dysfunction include, among others, decreased levels of ATP production, decreased levels of metabolites, decreased levels of antioxidant defense, and an increased mitochondrial permeability transition pore (MPTP) transport of cytochrome c, all of which are highly detrimental to both mitochondria and consequently neurons. See text for more details.

Based on the hypothesis that $A\beta$ -induced oxidative damage to mitochondria is an early event in the progression of AD, mitochondria have been targeted for the study and development of therapeutics [53,147,148]. This is still a rather nascent field of investigation, and further studies are needed. Toward this goal, a recent compilation of mitochondria-targeted therapeutic strategies for AD was published [148]. Among these mitochondria-targeted therapeutic agents are those that target mitochondrial: bioenergetics; glucose metabolism; biogenesis; uncoupling proteins; mitophagy; and oxidative stress. In keeping with the theme of this review, we discuss the latter. Alpha-lipoic acid is a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, which are key components in glucose metabolism; when given to dogs and rodents, it decreases oxidative damage in the brain and improves cognition [149,150]. In a small clinical pilot study, probable AD patients given alpha-lipoic acid and two choline acetyltransferase (CAT) inhibitors had slower cognitive decline than probable AD patients given only the two CAT inhibitors [151]. Another mitochondria-targeted therapeutic agent is coenzyme Q10 (CoQ10), which is a key participant in the Q-cycle of electron transport in the inner mitochondrial membrane. CoQ10 led to decreased $A\beta$ pathology in aged transgenic mice with human AD *presenilin-1* mutation, and in a different study, a quinone-containing derivative of CoQ10 (MitoQ) that targets mitochondria, improved memory, and neuropathology in a transgenic mouse model of AD [152,153]. Continued development of mitochondria-targeted therapeutic agents will be important for strategies to slow or stop the progression of AD.

While age, chromosomal sex, family history, and *apoE* genotype remain the primary risk factors for the development of AD [154,155], there are several controllable risk factors including obesity [156,157], hyperlipidemia [158,159], hypertension [160–163], type 2 diabetes [164–167], and sedentary lifestyle [168] that can be addressed in an effort to decrease the risk of developing AD. Mitochondrial oxidative stress is increased by the consumption of excess calories and, in turn, it leads to mitochondrial DNA damage [120], which has been described in an AD brain [169,170] in which base deletions correlate with complex IV deficiency in an AD hippocampus [171]. Collectively, this suggests that eating a heart-healthy diet [172–176] and increasing physical activity [177–180] could

delay the onset of AD. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) multidomain lifestyle intervention trial found that interventions in nutrition, exercise, cognitive training, and management of metabolic and vascular risk factors benefitted an at-risk population [181], even in *APOEε4* carriers [182]; however, no significant differences in brain volume or cortical thickness were determined by MRI after two years of intervention [183]. This suggests that two years is not enough or that the intervention, while improving cognitive processing speed, is too late to impact brain volume and may be more effective if implemented earlier in life. Given the similarity in mitochondrial dysfunction observed in obesity, type 2 diabetes, and AD [184–187], it is reasonable to hypothesize that these lifestyle interventions, if implemented in midlife or earlier, may protect against the mitochondrial dysfunction evident in AD.

7. Concluding Remarks

Alzheimer disease represents a worldwide public health crisis that is expanding due to improvements in health care that permits increased longevity among people. The economic and personal costs are staggering already, and the implications for the future are highly daunting. Consequently, new insights into ways to slow the progression of AD are a high priority among nations of the world.

Important components of the pathogenesis and progression of AD are oxidative and nitrosative stress in brain. Mitochondria provide reactive oxygen species that contribute to both oxidative and nitrosative stress and are themselves targets of these free radical-mediated processes. Consequently, we posit that better understanding of the molecular processes that lead to mitochondrial oxidative and nitrosative stress potentially will lead to selective therapeutic targets in mitochondria that slow or retard the progression of AD.

In this review, we trust that we have increased interest in the AD research community for investigations designed to gain additional much-needed understanding of the molecular basis of AD that, we assert, ought to include studies of mitochondria in this devastating disorder.

Funding: This work was funded in part by a grant from the National Institutes of Health [R01AG060056] (D.A.B.). The APC was funded by the same grant.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Katzman, R.; Saitoh, T. Advances in Alzheimer's disease. *FASEB J.* **1991**, *5*, 278–286. [[CrossRef](#)] [[PubMed](#)]
2. Nelson, P.T.; Braak, H.; Markesbery, W.R. Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. *J. Neuropathol. Exp. Neurol.* **2009**, *68*, 1–14. [[CrossRef](#)] [[PubMed](#)]
3. Li, S.; Selkoe, D.J. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A β oligomers from Alzheimer's brain. *J. Neurochem.* **2020**, in press. [[CrossRef](#)]
4. Scheff, S.W.; Price, D.A. Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. *J. Alzheimers Dis.* **2006**, *9* (Suppl. 3), 101–115. [[CrossRef](#)]
5. Panza, F.; Lozupone, M.; Logroscino, G.; Imbimbo, B.P. A critical appraisal of amyloid- β -targeting therapies for Alzheimer disease. *Nat. Rev. Neurol.* **2019**, *15*, 73–88. [[CrossRef](#)]
6. Petersen, R.C. Mild cognitive impairment: Current research and clinical implications. *Semin. Neurol.* **2007**, *27*, 22–31. [[CrossRef](#)]
7. Markesbery, W.R. Neuropathologic alterations in mild cognitive impairment: A review. *J. Alzheimers Dis.* **2010**, *19*, 221–228. [[CrossRef](#)]
8. Butterfield, D.A.; Halliwell, B. Oxidative stress, glucose dysmetabolism and Alzheimer disease. *Nat. Rev. Neurosci.* **2019**, *20*, 148–160. [[CrossRef](#)]
9. Butterfield, D.A.; Drake, J.; Pocernich, C.; Castegna, A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. *Trends Mol. Med.* **2001**, *7*, 548–554. [[CrossRef](#)]

10. Wang, X.; Wang, W.; Li, L.; Perry, G.; Hyung-gon Lee, H.-G.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochim. Biophys. Acta* **2014**, *1842*, 1240–1247. [[CrossRef](#)]
11. Keller, J.N.; Schmitt, F.A.; Scheff, S.W.; Ding, Q.; Chen, Q.; Butterfield, D.A.; Markesbery, W.R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. *Neurology* **2005**, *64*, 1152–1156. [[CrossRef](#)] [[PubMed](#)]
12. Butterfield, D.A. The 2013 SFRBM Discovery Award: Selected discoveries from the Butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. *Free Radic. Biol. Med.* **2014**, *74*, 157–174. [[CrossRef](#)] [[PubMed](#)]
13. Halliwell, B.; Gutteridge, J.M.C. *Free Radicals in Biology & Medicine*, 5th ed.; Oxford University Press: New York, NY, USA, 2015.
14. van der Bliek, A.M.; Margaret, M.; Sedensky, M.M.; Morgan, P.G. Cell biology of the mitochondrion. *Genetics* **2017**, *207*, 843–871. [[CrossRef](#)] [[PubMed](#)]
15. Ren, X.; Keeney, J.T.R.; Miriyala, S.; Noel, T.; Powell, D.K.; Chaiswing, L.; Bondada, S.; St. Clair, D.K.; Butterfield, D.A. Bottom of Form the triangle of death of neurons: Oxidative damage, mitochondrial dysfunction, and loss of choline-containing biomolecules in brains of mice treated with doxorubicin. Advanced insights into mechanisms of chemotherapy induced cognitive impairment (“chemobrain”) involving TNF- α . *Free Radic. Biol. Med.* **2019**, *134*, 1–8. [[PubMed](#)]
16. Dhar, S.K.; St. Clair, D.K. Manganese superoxide dismutase regulation and cancer. *Free Radic. Biol. Med.* **2012**, *52*, 2209–2222. [[CrossRef](#)]
17. Nelson, S.K.; Bose, S.K.; Grunwald, G.K.; Myhill, P.; McCord, J.M. The induction of human superoxide dismutase and catalase in vivo: A fundamentally new approach to antioxidant therapy. *Free Radic. Biol. Med.* **2006**, *40*, 341–347. [[CrossRef](#)]
18. Sies, H.; Brendt, C.; Jones, D.P. Oxidative stress. *Annu. Rev. Biochem.* **2017**, *86*, 715–748. [[CrossRef](#)]
19. Rhee, S.G.; Kil, I.S. Multiple functions and regulation of mammalian peroxiredoxin. *Annu. Rev. Biochem.* **2017**, *86*, 749–775. [[CrossRef](#)]
20. Maiorino, M.; Conrad, M.; Ursini, F. GPx4, lipid peroxidation, and cell death: Discoveries, rediscoveries, and open issues. *Antioxid. Redox Signal.* **2018**, *29*, 61–74. [[CrossRef](#)]
21. Jiang, B.; Moskovitz, J. The functions of the mammalian methionine reductase systems and related diseases. *Antioxidants* **2018**, *7*, 122. [[CrossRef](#)]
22. Butterfield, D.A.; Stadtman, E.R. Protein oxidation processes in aging brain. *Adv. Cell Aging Gerontol.* **1997**, *2*, 161–191.
23. Tramutola, A.; Lanzillotta, C.; Perluigi, M.; Butterfield, D.A. Oxidative stress, protein modification and Alzheimer disease. *Brain Res. Bull.* **2017**, *133*, 88–96. [[CrossRef](#)] [[PubMed](#)]
24. Ren, X.; Hinchie, A.; Swomley, A.; Powell, D.K.; Butterfield, D.A. Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of *PINK1* knockout rats as functions of age and gender: Relevance to parkinson disease. *Free Radic. Biol. Med.* **2019**, *143*, 146–152. [[CrossRef](#)] [[PubMed](#)]
25. Higdon, A.N.; Landar, A.; Barnes, S.; Darley-USmar, V.M. The electrophile responsive proteome: Integrating proteomics and lipidomics with cellular function. *Antioxid. Redox Signal.* **2012**, *17*, 1580–1589. [[CrossRef](#)]
26. Lauderback, C.M.; Hackett, J.M.; Huang, F.F.; Keller, J.N.; Szweda, L.I.; Markesbery, W.R.; Butterfield, D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-Hydroxy-2-nonenal in the Alzheimer's disease brain: Role of A β 1-42. *J. Neurochem.* **2001**, *78*, 413–416. [[CrossRef](#)]
27. Hardas, S.S.; Sultana, R.; Clark, A.M.; Bracket, C.; Szweda, L.I.; Murphy, M.P.; Butterfield, D.A. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. *Redox Biol.* **2013**, *1*, 80–85. [[CrossRef](#)]
28. Subramaniam, R.; Roediger, F.; Jordan, B.; Mattson, M.P.; Keller, J.N.; Waeg, G.; Butterfield, D.A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. *J. Neurochem.* **1997**, *69*, 1161–1169. [[CrossRef](#)]
29. Radi, R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 5839–5848. [[CrossRef](#)]
30. Batthyány, C.; Bartesaghi, S.; Mastrogiovanni, M.; Lima, A.; Demicheli, V.; Radi, R. Tyrosine-nitrated proteins: Proteomic and bioanalytical aspects. *Antioxid. Redox Signal.* **2017**, *26*, 313–328. [[CrossRef](#)]
31. Huang, Y.; Mahley, R.W. Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. *Neurobiol. Dis.* **2014**, *72 Pt A*, 3–12. [[CrossRef](#)]

32. Wisniewski, T.; Drummond, E. APOE-amyloid interaction: Therapeutic targets. *Neurobiol. Dis.* **2020**, *138*, 104784. [[CrossRef](#)] [[PubMed](#)]
33. Butterfield, D.A.; Mattson, M.P. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer disease. *Neurobiol. Dis.* **2020**, *138*, 104795. [[CrossRef](#)] [[PubMed](#)]
34. Swerdlow, R.H. Mitochondria and Mitochondrial Cascades in Alzheimer's disease. *J. Alzheimers Dis.* **2018**, *62*, 1403–1416. [[CrossRef](#)] [[PubMed](#)]
35. Butterfield, D.A.; Boyd-Kimball, D. Redox proteomics and amyloid β -peptide: Insights into Alzheimer disease. *J. Neurochem.* **2019**, *151*, 459–487. [[CrossRef](#)]
36. Sultana, R.; Mecocci, P.; Mangialasche, F.; Cecchetti, R.; Butterfield, D.A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer disease: Insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. *J. Alzheimers Dis.* **2011**, *24*, 77–84.
37. Sultana, R.; Baglioni, M.; Cecchetti, R.; Cai, J.; Klein, J.B.; Bastiani, P.; Ruggiero, C.; Mecocci, P.; Butterfield, D.A. Lymphocyte mitochondria: Toward identification of peripheral biomarkers in progression of Alzheimer disease. *Free Radic. Biol. Med.* **2013**, *65*, 595–606. [[CrossRef](#)]
38. Youle, R.J.; van der Bliek, A.M. Mitochondrial fission, fusion, and stress. *Science* **2012**, *337*, 1062–1065. [[CrossRef](#)]
39. Oliver, D.M.A.; Reddy, P.H. Molecular biology of Alzheimers disease: Focus on mitochondria. *J. Alzheimers Dis.* **2019**, *72*, S95–S116. [[CrossRef](#)]
40. Baek, S.H.; Park, S.J.; Jeong, J.I.; Kim, S.H.; Han, J.; Kyung, J.W.; Baik, S.-H.; Choi, Y.; Choi, B.Y.; Park, J.S.; et al. Inhibition of Drp1 ameliorates synaptic depression, A β deposition, and cognitive impairment in an Alzheimer's disease model. *J. Neurosci.* **2017**, *37*, 5099–5110. [[CrossRef](#)]
41. Wang, W.; Yin, J.; Ma, X.; Zhao, F.; Siedlak, S.L.; Wang, Z.; Torres, S.; Fujioka, H.; Xu, Y.; Perry, G.; et al. Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model. *Hum. Mol. Genet.* **2017**, *26*, 4118–4131. [[CrossRef](#)]
42. Reddy, P.H.; Manczak, M.; Yin, X. Mitochondrial-division inhibitor 1 protects against amyloid-b induced mitochondrial fragmentation and synaptic damage in Alzheimer's disease. *J. Alzheimers Dis.* **2017**, *58*, 147–162. [[CrossRef](#)] [[PubMed](#)]
43. Dalle-Donne, I.; Scaloni, A.; Butterfield, D.A. *Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases*; Wiley Press: New York, NY, USA, 2006.
44. Castegna, A.; Aksenov, M.; Aksenova, M.; Thongboonkerd, V.; Klein, J.B.; Pierce, W.M.; Booze, R.; Markesbery, W.R.; Butterfield, D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic. Biol. Med.* **2002**, *33*, 562–571. [[CrossRef](#)]
45. Butterfield, D.A.; Perluigi, M.; Reed, T.; Muharib, T.; Hughes, C.P.; Robinson, R.A.; Sultana, R. Redox proteomics in selected neurodegenerative disorders. From its infancy to future applications. *Antioxidant. Redox Signal.* **2012**, *17*, 1610–1655. [[CrossRef](#)] [[PubMed](#)]
46. Butterfield, D.A.; Gu, L.; Di Domenico, F.; Robinson, R.A.S. Mass spectrometry and redox proteomics: Applications in disease. *Mass Spectrom. Rev.* **2014**, *33*, 277–301. [[CrossRef](#)] [[PubMed](#)]
47. Sultana, R.; Perluigi, M.; Butterfield, D.A. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into mechanism of neurodegeneration from redox proteomics. *Antioxidant. Redox Signal.* **2006**, *8*, 2021–2037. [[CrossRef](#)]
48. Perluigi, M.; Coccia, R.; Butterfield, D.A. 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: A toxic combination illuminated by redox proteomics Studies. *Antioxidant. Redox Signal.* **2012**, *17*, 590–1609. [[CrossRef](#)]
49. Sultana, R.; Perluigi, M.; Butterfield, D.A. Lipid peroxidation triggers Neurodegeneration: A redox proteomics view into the Alzheimer disease brain. *Free Radic. Biol. Med.* **2013**, *62*, 157–169. [[CrossRef](#)]
50. Perluigi, M.; Swomley, A.M.; Butterfield, D.A. Redox proteomics and the dynamic molecular landscape of the aging brain. *Ageing Res. Rev.* **2014**, *13*, 75–89. [[CrossRef](#)]
51. Butterfield, D.A.; Di Domenico, F.; Swomley, A.M.; Head, E.; Perluigi, M. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down syndrome and Alzheimer disease brain. *Biochem. J.* **2014**, *463*, 177–189. [[CrossRef](#)]

52. Di Domenico, F.; Barone, E.; Perluigi, M.; Butterfield, D.A. The triangle of death in Alzheimer disease brain: The aberrant cross talk among energy metabolism, mTOR signaling and protein homeostasis revealed by redox proteomics. *Antioxidant. Redox Signal.* **2017**, *26*, 364–387. [[CrossRef](#)]
53. Reddy, P.H.; Tripathi, R.; Troung, Q.; Tirumala, K.; Reddy, T.P.; Anekonda, V.; Shirendeb, U.P.; Calkins, M.J.; Reddy, A.P.; Mao, P.; et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. *Biochim. Biophys. Acta* **2012**, *1822*, 639–649. [[CrossRef](#)]
54. Perluigi, M.; Sultana, R.; Cenini, G.; Di Domenico, F.; Memo, M.; Pierce, W.M.; Coccia, R.; Butterfield, D.A. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. *Proteom. Clin. Appl.* **2009**, *3*, 682–693. [[CrossRef](#)] [[PubMed](#)]
55. Reed, T.T.; Pierce, W.M.; Markesbery, W.R.; Butterfield, D.A. Proteomic identification of HNE-bound proteins in early Alzheimer's disease: Insights into the role of lipid peroxidation in the progression of AD. *Brain Res.* **2009**, *1274*, 66–76. [[CrossRef](#)] [[PubMed](#)]
56. Reed, T.; Perluigi, M.; Sultana, R.; Pierce, W.M.; Klein, J.B.; Turner, D.M.; Coccia, R.; Markesbery, W.R.; Butterfield, D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnesic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. *Neurobiol. Dis.* **2008**, *30*, 107–120. [[CrossRef](#)] [[PubMed](#)]
57. Sultana, R.; Poon, H.F.; Cai, J.; Pierce, W.M.; Merchant, M.; Klein, J.B.; Markesbery, W.R.; Butterfield, D.A. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. *Neurobiol. Dis.* **2006**, *22*, 76–87. [[CrossRef](#)] [[PubMed](#)]
58. Sultana, R.; Reed, T.; Perluigi, M.; Coccia, R.; Pierce, W.M.; Butterfield, D.A. Proteomic identification of nitrated brain proteins in amnesic mild cognitive impairment: A regional study. *J. Cell. Molec. Med.* **2007**, *11*, 839–851. [[CrossRef](#)] [[PubMed](#)]
59. Sultana, R.; Perluigi, M.; Newman, S.F.; Pierce, W.M.; Cini, C.; Coccia, R.; Butterfield, D.A. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. *Antioxid. Redox Signal.* **2010**, *12*, 327–336. [[CrossRef](#)]
60. Aluise, C.D.; Robinson, R.A.S.; Cai, J.; Pierce, W.M.; Markesbery, W.R.; Butterfield, D.A. Redox proteomics analysis of brains from subjects with amnesic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: Insights into memory loss in MCI. *J. Alzheimers Dis.* **2011**, *23*, 257–269. [[CrossRef](#)]
61. Terni, B.; Boada, J.; Portero-Otin, M.; Ramplona, R.; Ferrer, I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology. *Brain Path.* **2010**, *20*, 222–233. [[CrossRef](#)]
62. Lushchak, O.; Piroddi, M.; Galli, F.; Lushchak, V.I. Aconitase post-translational modification as a key in linkage between Krebs cycle, iron homeostasis, redox signaling, and metabolism of reactive oxygen species. *Redox Rep.* **2014**, *19*, 8–15. [[CrossRef](#)]
63. Shen, L.; Chen, C.; Yang, A.; Chen, Y.; Liu, Q.; Ni, J. Redox proteomics identification of specifically carbonylated proteins in the hippocampi of triple transgenic Alzheimer's disease mice at its earliest pathological stage. *J. Proteomics* **2015**, *123*, 101–113. [[CrossRef](#)] [[PubMed](#)]
64. Minárik, P.; Tomášková, N.; Kollárová, M.; Antalík, M. Malate Dehydrogenases—Structure and Function. *Gen. Physiol. Biophys.* **2002**, *21*, 257–265. [[PubMed](#)]
65. Sultana, R.; Newman, S.F.; Mohammad-Abdul, H.; Cai, J.; Pierce, W.M.; Klein, J.B.; Merchant, M.; Butterfield, D.A. Protective Effect of D609 Against Amyloid-Beta1-42-Induced Oxidative Modification of Neuronal Proteins: Redox Proteomics Study. *J. Neurosci. Res.* **2006**, *84*, 409–417. [[CrossRef](#)] [[PubMed](#)]
66. Boyd-Kimball, D.; Poon, H.F.; Lynn, B.C.; Cai, J.; Pierce, W.M., Jr.; Klein, J.B.; Ferguson, J.; Link, C.D.; Butterfield, D.A. Proteomic identification of proteins specifically oxidized in *Caenorhabditis elegans* expressing human A β (1-42): Implications for Alzheimer's Disease. *Neurobiol. Aging* **2006**, *27*, 1239–1249. [[CrossRef](#)] [[PubMed](#)]
67. Hashimoto, T.; Hussien, R.; Cho, H.-S.; Kaufer, D.; Brooks, G.A. Evidence for the mitochondrial lactate oxidation complex in rat neurons: Demonstration of an essential component of brain lactate shuttles. *PLoS ONE* **2008**, *3*, e2915. [[CrossRef](#)] [[PubMed](#)]

68. Bittar, P.G.; Charnay, Y.; Pellerin, L.; Bouras, C.; Magistretti, P.J. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. *J. Cereb. Blood Flow Met.* **1996**, *16*, 1079–1089. [[CrossRef](#)]
69. Wyss, M.T.; Jolivet, R.; Buck, A.; Magistretti, P.J.; Weber, B. In vivo evidence for lactate as a neuronal energy source. *J. Neurosci.* **2011**, *31*, 7477–7485. [[CrossRef](#)]
70. Hui, S.; Ghergurovich, J.M.; Morscher, R.J.; Jang, C.; Teng, X.; Lu, W.; Esparza, L.A.; Reya, T.; Zhan, L.; Guo, J.Y.; et al. Glucose feeds the TCA cycle via circulating lactate. *Nature* **2017**, *551*, 115–118. [[CrossRef](#)]
71. Wallace, D.C. Bioenergetic origins of complexity of disease. *Cold Spring Harb. Symp. Quant. Biol.* **2011**, *76*, 1–16. [[CrossRef](#)]
72. Yellen, G. Fueling thought: Management of glycolysis and oxidative phosphorylation in neuronal metabolism. *J. Cell Biol.* **2018**, *217*, 2235–2246. [[CrossRef](#)]
73. Sultana, R.; Robinson, R.A.S.; Di Domenico, F.; Abdul, H.M.; St. Clair, D.K.; Markesbery, W.R.; Cai, J.; Pierce, W.M.; Butterfield, D.A. Proteomics identification of specifically carbonylated brain proteins in APP^{NLh}/APP^{NLh} × PS-1^{P264L}/PS-1^{P264L} human double mutant knock-in mice model of Alzheimer disease as a function of age. *J. Proteom.* **2011**, *74*, 2430–2440.
74. Small, G.W.; Ercoli, L.M.; Silverman, D.H.S.; Huang, S.-C.; Komo, S.; Bookheimer, S.Y.; Lavretsky, H.; Miller, K.; Siddarth, P.; Rasgon, N.L.; et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 6037–6042. [[CrossRef](#)] [[PubMed](#)]
75. Mosconi, L.; De Santi, S.; Li, J.; Tsui, W.H.; Li, Y.; Boppana, M.; Laska, E.; Rusinek, H.; de Leon, M.J. Hippocampal hypometabolism predicts cognitive decline from normal aging. *Neurobiol. Aging* **2008**, *29*, 676–692. [[CrossRef](#)]
76. Mosconi, L.; Mistur, R.; Switalski, R.; Tsui, W.H.; Glodzik, L.; Li, Y.; Pirraglia, E.; De Santi, S.; Reisberg, B.; Wisniewski, T.; et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. *Eur. J. Nucl. Med. Imaging* **2009**, *36*, 811–822. [[CrossRef](#)] [[PubMed](#)]
77. Castro, J.P.; Wardelmann, K.; Grune, T.; Kleinridders, A. Mitochondrial chaperones in brain: Safeguarding brain health and metabolism? *Front. Endocrinol.* **2018**, *9*, 196. [[CrossRef](#)]
78. DeBalsi, K.L.; Hoff, K.E.; Copeland, W.C. Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. *Ageing Res. Rev.* **2017**, *33*, 89–104. [[CrossRef](#)]
79. Maracci, C.; Rodnina, M.V. Review: Translational GTPases. *Biopolymers* **2016**, *105*, 463–475. [[CrossRef](#)]
80. Young, J.C.; Hoogenraad, N.J.; Hartl, F.U. Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. *Cell* **2003**, *112*, 41–50. [[CrossRef](#)]
81. Holley, A.K.; Bakthavatchalu, V.; Velez-Roman, J.M.; St. Clair, D.K. Manganese Superoxide Dismutase: Guardian of the Powerhouse. *Int. J. Mol. Sci.* **2011**, *12*, 7114–7162. [[CrossRef](#)]
82. Holley, A.K.; Dhar, S.K.; Xu, Y.; St. Clair, D.K. Manganese superoxide dismutase: Beyond life and death. *Amino Acids* **2012**, *42*, 139–158. [[CrossRef](#)]
83. Flynn, J.M.; Melov, S. SOD2 in mitochondrial dysfunction and neurodegeneration. *Free Rad. Biol. Med.* **2013**, *62*, 4–12. [[CrossRef](#)] [[PubMed](#)]
84. Marcus, D.L.; Strafaci, J.A.; Freedman, M.L. Differential neuronal expression of manganese superoxide dismutase in Alzheimer’s disease. *Med. Sci. Monit.* **2006**, *12*, BR8–BR14. [[PubMed](#)]
85. Zhao, Y.; Chaiswing, L.; Velez, J.M.; Batinic-Haberle, I.; Colburn, N.H.; Oberley, T.D.; St. Clair, D.K. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. *Cancer Res.* **2005**, *65*, 3745–3750. [[CrossRef](#)] [[PubMed](#)]
86. Dai, C.-Q.; Luo, T.-T.; Luo, S.-C.; Wang, J.-Q.; Wang, S.-M.; Bai, Y.-H.; Yang, Y.-L.; Wang, Y.-Y. p53 mitochondrial dysfunction: Novel insight of neurodegenerative disease. *J. Bioenerg. Biomembr.* **2016**, *48*, 337–347. [[CrossRef](#)] [[PubMed](#)]
87. Cenini, G.; Sultana, R.; Memo, M.; Butterfield, D.A. Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnesic mild cognitive impairment and Alzheimer’s disease. *Free Rad. Biol. Med.* **2008**, *45*, 81–85. [[CrossRef](#)] [[PubMed](#)]
88. Cenini, G.; Sultana, R.; Memo, M.; Butterfield, D.A. Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnesic mild cognitive impairment and Alzheimer’s disease. *J. Cell. Mol. Med.* **2008**, *12*, 987–994. [[CrossRef](#)]

89. Fiorini, A.; Sultana, R.; Barone, E.; Cenini, G.; Perluigi, M.; Mancuso, C.; Cai, J.; Klein, J.B.; St. Clair, D.K.; Butterfield, D.A. Lack of p53 affects the expression of several brain mitochondrial proteins: Insights from proteomics in important pathways regulated by p53. *PLoS ONE* **2012**, *7*, e49846. [[CrossRef](#)]
90. Drane, P.; Bravard, A.; Bouvard, V.; May, E. Reciprocal down-regulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis. *Oncogene* **2001**, *20*, 430–439. [[CrossRef](#)]
91. Dhar, S.K.; Tangpong, J.; Chaiswing, L.; Oberley, T.D.; St. Clair, D.K. Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stages. *Cancer Res.* **2011**, *71*, 6684–6695. [[CrossRef](#)]
92. Barone, E.; Cenini, G.; Di Domenico, F.; Noel, T.; Wang, C.; Perluigi, M.; St. Clair, D.K.; Butterfield, D.A. Basal brain oxidative and nitrosative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. *J. Neurosci. Res.* **2015**, *93*, 1728–1739. [[CrossRef](#)]
93. Tramutola, A.; Pupo, G.; Di Domenico, F.; Barone, E.; Arena, A.; Lanzillotta, C.; Brokekaart, D.; Blarmino, C.; Head, E.; Butterfield, D.A.; et al. Activation of p53 in Down Syndrome and in the Ts65Dn mouse brain is associated with a pro-apoptotic phenotype. *J. Alzheimers Dis.* **2016**, *52*, 359–371. [[CrossRef](#)] [[PubMed](#)]
94. Shoshan-Barmatz, V.; Nahon-Crystal, E.; Shteinfer-Kuzmine, A.; Gupta, R. VDAC1, mitochondrial dysfunction, and Alzheimer's disease. *Pharmacol. Res.* **2018**, *131*, 87–101. [[CrossRef](#)] [[PubMed](#)]
95. Shoshan-Barmatz, V.; Maldonado, E.N.; Krelin, Y. VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress. *Cell Stress* **2017**, *1*, 11–36. [[CrossRef](#)] [[PubMed](#)]
96. Geula, S.; Naveed, H.; Liang, J.; Shoshan-Barmatz, V. Structure-based analysis of VDAC1 protein: Defining oligomer contact sites. *J. Biol. Chem.* **2012**, *287*, 2179–2190. [[CrossRef](#)]
97. Geula, S.; Ben-Hail, D.; Shoshan-Barmatz, V. Structure-based analysis of VDAC1: N-terminus location, translocation, channel gating and association with anti-apoptotic proteins. *Biochem. J.* **2012**, *444*, 475–485. [[CrossRef](#)]
98. Shi, Y.; Chen, J.; Weng, C.; Chen, R.; Zheng, Y.; Chen, Q.; Tang, H. Identification of the protein-protein contact site and interaction mode of human VDAC1 with Bcl-2 family proteins. *Biochem. Biophys. Res. Commun.* **2003**, *305*, 989–996. [[CrossRef](#)]
99. Abu-Hamad, S.; Arbel, N.; Calo, D.; Arzoine, L.; Israelson, A.; Keinan, N.; Ben-Romano, R.; Friedman, O.; Shoshan-Barmatz, V. The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. *J. Cell. Sci.* **2009**, *122*, 1906–1916. [[CrossRef](#)]
100. Arbel, N.; Shoshan-Barmatz, V. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity. *J. Biol. Chem.* **2010**, *285*, 6053–6062. [[CrossRef](#)]
101. Arbel, N.; Ben-Hail, D.; Shoshan-Barmatz, S. Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. *J. Biol. Chem.* **2012**, *287*, 23152–23161. [[CrossRef](#)]
102. Ben-Hail, D.; Shoshan-Barmatz, V. VDAC1-interacting anion transport inhibitors inhibit VDAC1 oligomerization and apoptosis. *Biochim. Biophys. Acta* **2016**, *1863*, 1612–1623. [[CrossRef](#)] [[PubMed](#)]
103. Shoshan-Barmatz, V.; Krelin, Y.; Chen, Q. VDAC1 as a player in mitochondria-mediated apoptosis and target for modulating apoptosis. *Curr. Med. Chem.* **2017**, *24*, 4435–4446. [[PubMed](#)]
104. Manczak, M.; Reddy, P.H. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. *Hum. Mol. Genet.* **2012**, *21*, 5131–5146. [[CrossRef](#)] [[PubMed](#)]
105. Azoulay-Zohar, H.; Israelson, A.; Abu-Hamad, S.; Shoshan-Barmatz, V. In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. *Biochem. J.* **2004**, *377*, 347–355. [[CrossRef](#)] [[PubMed](#)]
106. Abu-Hamad, S.; Zaid, H.; Israelson, A.; Nahon, E.; Shoshan-Barmatz, V. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: Mapping the site of binding. *J. Biol. Chem.* **2008**, *283*, 13482–13490. [[CrossRef](#)]
107. Smilansky, A.; Dangoor, L.; Nakdimon, I.; Ben-Hail, D.; Mizrachi, D.; Shoshan-Barmatz, V. The voltage-dependent anion channel 1 mediates amyloid β toxicity and represents a potential target for Alzheimer disease therapy. *J. Biol. Chem.* **2015**, *290*, 30670–30683. [[CrossRef](#)]
108. Feldhaus, P.; Fraga, D.B.; Ghedim, F.V.; De Luca, R.D.; Bruna, T.D.; Heluany, M.; Matos, M.P.; Ferreira, G.K.; Jeremias, I.C.; Heluany, C.; et al. Evaluation of respiratory chain activity in lymphocytes of patients with Alzheimer disease. *Metab. Brain Dis.* **2011**, *26*, 229–236. [[CrossRef](#)]

109. Parker, W.D., Jr.; Filley, C.M.; Parks, J.K. Cytochrome oxidase deficiency in Alzheimer's disease. *Neurology* **1990**, *40*, 1302–1303. [[CrossRef](#)]
110. Cardoso, S.M.; Proença, M.T.; Santos, S.; Santana, I.; Oliveira, C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. *Neurobiol. Aging* **2004**, *25*, 105–110. [[CrossRef](#)]
111. Bosetti, F.; Brizzi, F.; Barogi, S.; Mancuso, M.; Siciliano, G.; Tendi, E.A.; Murri, L.; Rapoport, S.I.; Solaini, G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. *Neurobiol. Aging* **2002**, *23*, 371–376. [[CrossRef](#)]
112. Mangialasche, F.; Baglioni, M.; Cecchetti, R.; Kivipelto, M.; Ruggiero, C.; Piobbico, D.; Kusmaul, L.; Monastero, R.; Brancorsini, S.; Mecocci, P. Lymphocytic mitochondrial aconitase activity is reduced in Alzheimer's disease and mild cognitive impairment. *J. Alzheimers Dis.* **2015**, *44*, 649–660. [[CrossRef](#)]
113. Zahid, S.; Khan, R.; Oellerid, M.; Ahmed, N.; Asif, A.R. Differential S-nitrosylation of proteins in Alzheimer's disease. *Neuroscience* **2014**, *256*, 126–136. [[CrossRef](#)] [[PubMed](#)]
114. Zareba-Kozioł, M.; Swajda, A.; Dadlez, M.; Wyslouch-Cieszynska, A. Global analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain: Clues for synaptic pathology. *Mol. Cell. Proteom.* **2014**, *13*, 2288–2305. [[CrossRef](#)] [[PubMed](#)]
115. Wijasa, T.S.; Sylveser, M.; Broche-Ahmadinejad, N.; Schwartz, S.; Santarelli, F.; Geiselman, V.; Klockgether, F.; Heneka, M.T. Quantitative proteomics of synaptosome S-nitrosylation in Alzheimer disease. *J. Neurochem.* **2020**, *152*, 710–726. [[CrossRef](#)] [[PubMed](#)]
116. Nakamura, T.; Prikhodko, O.A.; Pirie, E.; Nagar, S.; Akhtar, M.W.; Oh, C.-K.; McKercher, S.R.; Ambasadhan, R.; Okamoto, S.-I.; Lipton, S.A. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. *Neurobiol. Dis.* **2015**, *84*, 99–108. [[CrossRef](#)] [[PubMed](#)]
117. Butterfield, D.A.; Lauderback, C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. *Free Radic. Biol. Med.* **2002**, *32*, 1050–1060. [[CrossRef](#)]
118. Rolfe, D.F.S.; Brown, G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiol. Rev.* **1997**, *77*, 731–758. [[CrossRef](#)]
119. Bordone, M.P.; Salman, M.M.; Titus, H.E.; Amiri, E.; Andersen, J.V.; Chakraborti, B.; Diuba, A.V.; Dubouskaya, T.G.; Ehrke, E.; de Freitas, A.E.; et al. The energetic brain – A review from students to students. *J. Neurochem.* **2020**, *151*, 139–165. [[CrossRef](#)]
120. Wallace, D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. *Annu. Rev. Genet.* **2005**, *39*, 359–407. [[CrossRef](#)]
121. Falkowska, A.; Gutowska, I.; Goschorska, M.; Nowacki, P.; Chlubek, D.; Bawanowska-Basiacka, I. Energy metabolism of the brain, including the cooperation between astrocytes and neurons, especially in the context of glycogen metabolism. *Int. J. Mol. Sci.* **2015**, *16*, 25959–25981. [[CrossRef](#)]
122. Croteau, E.; Castellano, C.A.; Fortier, M.; Bocti, C.; Fulop, T.; Paquet, N.; Cunnane, S.C. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment, and early Alzheimer's disease. *Exp. Gerontol.* **2018**, *107*, 18–26. [[CrossRef](#)]
123. Croteau, E.; Castellano, C.-A.; Richard, M.A.; Fortier, M.; Nugent, S.; Lepage, M.; Duchesne, S.; Whittingstall, K.; Turcotte, E.E.; Bocti, C.; et al. Ketogenic medium chain triglycerides increase brain energy metabolism in Alzheimer's disease. *J. Alzheimers Dis.* **2018**, *64*, 551–561. [[CrossRef](#)] [[PubMed](#)]
124. Yip, J.; Geng, X.; Shen, J.; Ding, Y. Cerebral gluconeogenesis and diseases. *Front Pharmacol.* **2017**, *7*, 521. [[CrossRef](#)] [[PubMed](#)]
125. Gandhi, G.K.; Cruz, N.F.; Ball, K.K.; Diemel, G.A. Astrocytes are poised for lactate trafficking and release from activated brain and for supply of glucose to neurons. *J. Neurochem.* **2009**, *111*, 522–536. [[CrossRef](#)] [[PubMed](#)]
126. Mullarky, E.; Cantley, L.C. Diverting glycolysis to combat oxidative stress. In *Innovative Medicine: Basic Research and Development*; Nakao, K., Minato, N., Uemoto, S., Eds.; Springer: Tokyo, Japan, 2015; pp. 3–23.
127. Williams, H.C.; Farmer, B.C.; Piron, M.A.; Walsh, A.E.; Bruntz, R.C.; Gentry, M.S.; Sun, R.C.; Johnson, L.A. APOE alters glucose flux through central carbon pathways in astrocytes. *Neurobiol. Dis.* **2020**, *136*, 104742. [[CrossRef](#)]
128. Griffin, J.W.D.; Bradshaw, P.C. Amino acid catabolism in Alzheimer's disease brain: Friend or foe? *Oxid. Med. Cell. Longev.* **2017**, *2017*, 5472792. [[CrossRef](#)]
129. Cooper, A.J.; Jeitner, T.M. Central role of glutamate metabolism in the maintenance of nitrogen homeostasis in normal and hyperammonemic brain. *Biomolecules* **2016**, *6*, 16. [[CrossRef](#)]

130. Polis, B.; Samson, A.O. Role of the metabolism of branched-chain amino acids in the development of Alzheimer's disease and other metabolic disorders. *Neural Regen. Res.* **2020**, *15*, 1460–1470. [[CrossRef](#)]
131. Masliah, E.; Alford, M.; DeTeresa, R.; Mallory, M.; Hansen, L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. *Ann. Neurol.* **1996**, *40*, 759–766. [[CrossRef](#)]
132. Hertz, L.; Peng, L.; Dienel, G.A. Energy metabolism in astrocytes: High rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. *J. Cereb. Blood Flow Metab.* **2007**, *27*, 219–249. [[CrossRef](#)]
133. Smith, C.D.; Carney, J.M.; Starke-Reed, P.E.; Oliver, C.N.; Stadtman, E.R.; Floyd, R.A. Excess brain protein oxidation and enzyme dysfunction in normal and Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **1991**, *87*, 10540–10543. [[CrossRef](#)]
134. Hensley, K.; Hall, N.; Subramaniam, R.; Cole, R.; Harris, M.; Aksenov, M.; Aksenova, A.; Gabbita, S.P.; Wu, J.F.; Carney, J.M.; et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. *J. Neurochem.* **1995**, *65*, 2146–2156. [[CrossRef](#)] [[PubMed](#)]
135. Toledo, J.B.; Arnold, M.; Kastenmüller, G.; Chang, R.; Baillie, R.A.; Han, X.; Thambisetty, M.; Tenenbaum, J.D.; Suhre, K.; Thompson, J.W.; et al. The Alzheimer's Disease Neuroimaging Initiative and the Alzheimer's Disease Metabolomics Consortium. Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimers Dement.* **2017**, *13*, 965–984. [[CrossRef](#)] [[PubMed](#)]
136. González-Domínguez, R.; García-Barrera, T.; Gómez-Ariza, J.L. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease. *J. Pharm. Biomed. Anal.* **2015**, *107*, 75–81. [[CrossRef](#)] [[PubMed](#)]
137. Jack, C.R., Jr.; Lowe, V.J.; Weigand, S.D.; Wiste, H.J.; Senjem, M.L.; Knopman, D.S.; Shiung, M.M.; Gunter, J.L.; Boeve, B.F.; Kemp, B.J.; et al. The Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. *Brain* **2009**, *132*, 1355–1365. [[CrossRef](#)] [[PubMed](#)]
138. Bateman, R.J.; Xiong, C.; Benzinger, T.L.S.; Fagan, A.M.; Goate, A.; Fox, N.C.; Marcus, D.S.; Cairns, N.J.; Xie, X.; Blazey, T.M.; et al. Clinical and biomarker changes in dominantly inherited Alzheimer's Disease. *N. Engl. J. Med.* **2012**, *367*, 795–804. [[CrossRef](#)] [[PubMed](#)]
139. Reiman, E.M.; Zuiroz, Y.T.; Fleisher, A.S.; Chen, K.; Velez-Pardo, C.; Jimenez-Del-Rio, M.; Fagan, A.M.; Shah, A.R.; Alvarez, S.; Arbelaez, A.; et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. *Lancet Neurol.* **2012**, *11*, 1048–1056. [[CrossRef](#)]
140. Villemagne, V.L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K.A.; Salvador, O.; Szoeker, C.; Macaulay, S.L.; Martins, R.; Maruff, P.; et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *Lancet Neurol.* **2013**, *12*, 357–367. [[CrossRef](#)]
141. Gordon, B.A.; Blazey, T.M.; Su, Y.; Hari-Raj, A.; Dincer, A.; Flores, S.; Christensen, J.; McDade, E.; Wang, G.; Xiong, C.; et al. Spatial patterns of neuroimaging biomarker change in individual from families with autosomal dominant Alzheimer's disease: A longitudinal study. *Lancet Neurol.* **2018**, *17*, 241–250. [[CrossRef](#)]
142. Butterfield, D.A.; Boyd-Kimball, D. Oxidative stress, amyloid β -peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer's disease. *J. Alzheimers Dis.* **2018**, *62*, 1345–1367. [[CrossRef](#)]
143. Oda, T.; Wals, P.; Osterburg, H.H.; Johnson, S.A.; Pasinetti, G.M.; Morgan, T.E.; Rozovsky, I.; Stine, W.B.; Snyder, S.W.; Holzman, T.F.; et al. Clusterin (apoJ) alters the aggregation of amyloid β -peptide (A β 1-42) and forms slowly sedimenting A β complexes that cause oxidative stress. *Exp. Neurol.* **1995**, *136*, 22–31. [[CrossRef](#)]
144. Walsh, D.M.; Hartley, D.M.; Kusumoto, Y.; Fezoui, Y.; Condron, M.M.; Lomakin, A.; Benedek, G.B.; Selkoe, D.J.; Teplow, D.B. Amyloid beta-protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates. *J. Biol. Chem.* **1999**, *274*, 25945–25952. [[CrossRef](#)] [[PubMed](#)]
145. Lambert, J.C.; Mann, D.M.; Harris, J.M.; Chartier-Harlin, M.C.; Cumming, A.; Coates, J.; Lemmon, H.; St. Clair, D.K.; Iwatsubo, T.; Lendon, C. The -48 C/T polymorphism in the presenilin 1 promoter is associated with increased A β load in brain. *J. Med. Genet.* **2001**, *38*, 353–355. [[CrossRef](#)] [[PubMed](#)]
146. Drake, J.; Link, C.D.; Butterfield, D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic *Caenorhabditis elegans* model. *Neurobiol. Aging* **2003**, *24*, 415–420. [[CrossRef](#)]

147. Tobore, T.O. On the central role of mitochondria dysfunction and oxidative stress in Alzheimer's disease. *Neurol. Sci.* **2019**, *40*, 1527–1540. [[CrossRef](#)] [[PubMed](#)]
148. Lanzillotta, C.; Di Domenico, F.; Perluigi, M.; Butterfield, D.A. Targeting Mitochondria in Alzheimer disease: Rationale and perspectives. *CNS Drugs* **2019**, *33*, 957–969. [[CrossRef](#)]
149. Opii, W.O.; Joshi, G.; Head, E.; Milgram, N.W.; Muggenburg, B.A.; Klein, J.B.; Pierce, W.M.; Cotman, C.W.; Butterfield, D.A. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and program of behavioral enrichment: Relevance to Alzheimer's disease. *Neurobiol. Aging* **2008**, *29*, 51–70. [[CrossRef](#)]
150. Farr, S.A.; Poon, H.F.; Dogrukol-Ak, D.; Drake, J.; Banks, W.A.; Eyerman, E.; Butterfield, D.A.; Moreley, J.E. The antioxidants α -Lipoic Acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. *J. Neurochem.* **2003**, *84*, 1173–1183. [[CrossRef](#)]
151. Hager, K.; Marahrens, A.; Kenkies, M.; Riederer, P.; Munich, G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. *Arch. Gerontol. Geriatr.* **2001**, *32*, 275–282. [[CrossRef](#)]
152. Yang, X.; Yang, Y.; Li, G.; Wang, J.; Yang, E.S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. *J. Mol. Neurosci.* **2008**, *34*, 165–171. [[CrossRef](#)]
153. McManus, M.J.; Murphy, M.P.; Franklin, J.L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. *J. Neurosci.* **2011**, *31*, 15703–15715. [[CrossRef](#)]
154. Riedel, B.C.; Thompson, P.M.; Brinton, R.D. Age APOE and sex: Triad of risk of Alzheimer's disease. *J. Steroid Biochem. Mol. Biol.* **2016**, *160*, 134–147. [[CrossRef](#)] [[PubMed](#)]
155. Alzheimer's Association. 2020 Alzheimer's Disease Facts and Figures. *Alzheimers Dement.* **2020**, *16*, 391–460. [[CrossRef](#)] [[PubMed](#)]
156. Anstey, K.J.; Cherbuin, N.; Budge, M.; Young, J. Body mass index in midlife and late-life as a risk factor for dementia: A meta-analysis of prospective studies. *Obes. Rev.* **2011**, *12*, e426–e437. [[CrossRef](#)] [[PubMed](#)]
157. Albanese, E.; Launer, L.J.; Egger, M.; Prince, M.J.; Giannakopoulos, P.; Wolters, F.J.; Egan, K. Body mass index in midlife and dementia: Systemic review and meta-regression analysis of 589,649 men and women following in longitudinal studies. *Alzheimers Dement. (Amst.)* **2017**, *8*, 165–178. [[CrossRef](#)] [[PubMed](#)]
158. Soloman, A.; Kivipelto, M.; Wolozin, B.; Zhou, J.; Whitmer, R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. *Dement. Geriatr. Cogn. Disord.* **2009**, *28*, 75–80. [[CrossRef](#)]
159. Meng, X.F.; Yu, J.T.; Wang, H.F.; Tan, M.S.; Wang, C.; Tan, C.C.; Tan, L. Midlife vascular risk factors and the risk of Alzheimer's disease: A systematic review and meta-analysis. *J. Alzheimers Dis.* **2014**, *42*, 1295–1310. [[CrossRef](#)]
160. DeBette, S.; Seshadri, S.; Beiser, A.; Au, R.; Himali, J.J.; Palumbo, C.; Wolf, P.A.; DeCarli, C. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology* **2011**, *77*, 461–468. [[CrossRef](#)]
161. Ninomiya, T.; Ohara, T.; Hirakawa, Y.; Yoshida, D.; Hata, J.; Kanba, S.; Iwaki, T.; Kiyohara, Y. Midlife and late-life blood pressure and dementia in Japanese elderly: The Hisayama study. *Hypertension* **2011**, *58*, 22–28. [[CrossRef](#)]
162. Gottesman, R.F.; Albert, M.S.; Alonso, A.; Coker, L.H.; Coresh, J.; Davis, S.M.; Deal, J.A.; McKhann, G.M.; Mosley, T.H.; Sharrett, A.R.; et al. Associations between midlife vascular risk factors and 25-year incident dementia in atherosclerosis risk in communities (ARIC) cohort. *JAMA Neurol.* **2017**, *74*, 1246–1254. [[CrossRef](#)]
163. Livingston, G.; Sommerlad, A.; Orgeta, V.; Costafreda, S.G.; Huntley, J.; Ames, D.; Ballard, C.; Banerjee, S.; Burns, A.; Cohen-Mansfield, J.; et al. Dementia prevention, intervention, and care. *Lancet* **2017**, *390*, 2673–2734. [[CrossRef](#)]
164. Wu, W.; Brickman, A.M.; Luchsinger, J.; Ferrazzano, P.; Pichiule, P.; Yoshita, M.; DeCarli, C.; Barnes, C.A.; Mayeux, R.; Vannucci, S.J.; et al. The brain in the age of old: The hippocampal formation is targeted differentially by disease of late life. *Ann. Neurol.* **2008**, *64*, 698–706. [[CrossRef](#)] [[PubMed](#)]
165. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease. *Nat. Rev. Neurol.* **2011**, *7*, 137–152. [[CrossRef](#)] [[PubMed](#)]
166. Gudala, K.; Bansal, D.; Schifano, F.; Bhansali, A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. *J. Diabetes Investig.* **2013**, *4*, 640–650. [[CrossRef](#)] [[PubMed](#)]

167. Vagelatos, N.T.; Eslick, G.D. Type 2 diabetes as a risk factor for Alzheimer's disease: The confounders, interactions, and neuropathology associated with this relationship. *Epidemiol. Rev.* **2013**, *35*, 152–160. [[CrossRef](#)]
168. Santos-Lozano, A.; Pareja-Galeano, H.; Sanchis-Gomar, F.; Quindós-Rubial, M.; Fiuza-Luces, C.; Cristi-Montero, C.; Emanuele, E.; Garatachea, N.; Lucia, A. Physical activity and Alzheimer disease: A protective association. *Mayo Clin. Proc.* **2016**, *91*, 999–1020. [[CrossRef](#)]
169. Corral-Debrinski, M.; Horton, T.; Lott, M.T.; Shoffner, J.M.; McKee, A.C.; Beal, M.F.; Graham, B.H.; Wallace, D.C. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. *Genomics* **1994**, , [[CrossRef](#)]
170. Coskun, P.E.; Beal, M.F.; Wallace, D.C. Alzheimer's brain harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 10726–10731. [[CrossRef](#)]
171. Krishnan, K.J.; Ratnaik, T.E.; De Gruyter, H.L.M.; Jaros, E.; Turnbull, D.M. Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. *Neurobiol. Aging* **2012**, *33*, 2210–2214. [[CrossRef](#)]
172. Bargerger-Gateau, P.; Raffaitin, C.; Letenneur, L.; Tzourio, C.; Dartigues, J.F.; Alpérovitch, A. Dietary patterns and risk of dementia: The Three-City cohort study. *Neurology* **2007**, *69*, 1921–1930. [[CrossRef](#)]
173. Lourida, I.; Soni, M.; Thompson-Coon, J.; Purandare, N.; Lang, I.A.; Ukoumunne, O.C.; Llewellyn, D.J. Mediterranean diet, cognitive function, and dementia: A systematic review. *Epidemiology* **2013**, *24*, 479–489. [[CrossRef](#)]
174. Morris, M.C.; Tangney, C.C.; Wang, Y.; Sacks, F.M.; Barnes, L.L.; Bennett, D.A.; Aggarwal, N.T. MIND diet slows cognitive decline with aging. *Alzheimers Dement.* **2015**, *11*, 1015–1022. [[CrossRef](#)] [[PubMed](#)]
175. Morris, M.C.; Tangney, C.C.; Wang, Y.; Sacks, F.M.; Bennett, D.A.; Aggarwal, N.T. MIND diet associated with reduced incidence of Alzheimer's disease. *Alzheimers Dement.* **2015**, *11*, 1007–1014. [[CrossRef](#)] [[PubMed](#)]
176. Hardman, R.J.; Kennedy, G.; Macpherson, H.; Scholey, A.B.; Pipingas, A. Adherence to a Mediterranean-Style Diet and Effects on Cognition in Adults: A Qualitative Evaluation and Systematic Review of Longitudinal and Prospective Trials. *Front. Nutr.* **2016**, *3*, 22. [[CrossRef](#)] [[PubMed](#)]
177. Stephen, R.; Hongisto, K.; Solomon, A.; Lönnroos, E. Physical activity and Alzheimer's disease: A Systematic Review. *J. Gerontol. A Biol. Med. Sci.* **2017**, *72*, 733–739. [[CrossRef](#)] [[PubMed](#)]
178. Tan, Z.S.; Spartano, N.L.; Beiser, A.S.; DeCarli, C.; Auerbach, S.H.; Vasan, R.S.; Seshadri, S. Physical activity, brain volume, and dementia risk: The Framingham Study. *J. Gerontol. A Biol. Med. Sci.* **2017**, *72*, 789–795. [[CrossRef](#)] [[PubMed](#)]
179. Ogino, E.; Manly, J.J.; Schupf, N.; Mayeux, R.; Gu, Y. Current and past leisure time physical activity in relation to risk of Alzheimer's disease in older adults. *Alzheimers Dement.* **2019**, *15*, 1603–1611. [[CrossRef](#)]
180. Najjar, J.; Östling, S.; Gudmundsson, P.; Sundh, V.; Johansson, L.; Kern, S.; Guo, X.; Hällström, T.; Skoog, I. Cognitive and physical activity and dementia: A 44-year longitudinal population study of women. *Neurology* **2019**, *92*, e1322–e1330. [[CrossRef](#)]
181. Rosenberg, A.; Ngandu, T.; Rusanen, M.; Antikainen, R.; Bäckman, L.; Havulinna, S.; Hänninen, T.; Laatikainen, T.; Lehtisalo, J.; Levälahti, E.; et al. Multidomain lifestyle intervention benefits a large population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. *Alzheimers Dement.* **2018**, *14*, 263–270. [[CrossRef](#)]
182. Solomon, A.; Turunen, H.; Ngandu, T.; Peltonen, M.; Levälahti, E.; Seppo, H.; Antikainen, R.; Backman, L.; Hanninen, T.; Jula, A.; et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: A subgroup analysis of a randomized clinical trial. *JAMA Neurol.* **2018**, *75*, 462–470. [[CrossRef](#)]
183. Stephen, R.; Liu, Y.; Ngandu, T.; Antikainen, R.; Hulkkonen, J.; Koikkalainen, J.; Kemppainen, N.; Lötjönen, J.; Levälahti, E.; Parkkola, R.; et al. Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). *Alzheimers Res. Ther.* **2019**, *11*, 53. [[CrossRef](#)]
184. Bernardo, T.C.; Marques-Aleixo, I.; Beleza, J.; Oliveira, P.J.; Ascensão, A.; Magalhães, J. Physical exercise and brain mitochondrial fitness: The possible role against Alzheimer's disease. *Brain Pathol.* **2016**, *26*, 648–663. [[CrossRef](#)] [[PubMed](#)]

185. Pugazhenti, S.; Qin, L.; Reddy, P.H. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. *Biochim. Biophys. Acta Mol. Basis Dis.* **2017**, *1863*, 1037–1045. [[CrossRef](#)] [[PubMed](#)]
186. Cavalho, C.; Santos, M.S.; Oliveira, C.R.; Moreira, P.I. Alzheimer's disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers. *Biochim. Biophys. Acta* **2015**, *1852*, 1665–1675. [[CrossRef](#)] [[PubMed](#)]
187. Silzer, T.K.; Phillips, N.R. Etiology of type 2 diabetes and Alzheimer's disease: Exploring the mitochondria. *Mitochondrion* **2018**, *43*, 16–24. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).